The estimated Net Worth of Growth N Vbb Biotech Ag Bio... is at least $52.4 Million dollars as of 17 October 2023. Growth Bio owns over 400,000 units of Black Diamond Therapeutics Inc stock worth over $52,214,353 and over the last 10 years Growth sold BDTX stock worth over $146,835.
Growth has made over 63 trades of the Black Diamond Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Growth bought 400,000 units of BDTX stock worth $936,000 on 17 October 2023.
The largest trade Growth's ever made was buying 2,000,000 units of Black Diamond Therapeutics Inc stock on 26 October 2022 worth over $8,220,000. On average, Growth trades about 185,184 units every 53 days since 2014. As of 17 October 2023 Growth still owns at least 8,517,839 units of Black Diamond Therapeutics Inc stock.
You can see the complete history of Growth Bio stock trades at the bottom of the page.
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah und Capital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include: